These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 29122465

  • 1. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK, Lin HJ, Chua SK, Liao PC, Yang YP, Chou PC, Lee CW, Lin MJ, Chen HM, Yeh JT, Li YH.
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P.
    Drug Des Devel Ther; 2016 Feb; 10():1683-9. PubMed ID: 27274201
    [Abstract] [Full Text] [Related]

  • 3. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI.
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M.
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N, Morrill AM, Willett KC.
    Am J Ther; 2018 Feb; 25(3):e333-e338. PubMed ID: 27175894
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S, Coble K, Gansser D, Stangier J, Hoermann K, Pollack CV, Reilly P.
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
    Levy JH, van Ryn J, Sellke FW, Reilly PA, Elsaesser A, Glund S, Kreuzer J, Weitz JI, Pollack CV.
    Ann Surg; 2021 Sep 01; 274(3):e204-e211. PubMed ID: 31599808
    [Abstract] [Full Text] [Related]

  • 20. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
    Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangür H, Daffertshofer M, Edelbusch S, Gröschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Müllges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Röther J, Rossi R, Schäfer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R.
    Int J Stroke; 2017 Jun 01; 12(4):383-391. PubMed ID: 28494694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.